1.Survey participants reported that Oncology and Hematology (59%), Rare Diseases (39%), and Immunology and Rheumatology (38%) are the therapeutic areas leading their drug development pipeline
2. Challenges with patient recruitment in clinical trials (e.g., patient retention, population diversity) (55%) and increasing complexity of clinical trials (51%) are the biggest pain points for respondents’ organizations
3.The largest proportion of survey participants consider greater use of RWD/RWE to complement data from clinical trials (45%) and leveraging new technologies in drug development (e.g., mRNA, drug discovery platforms) (44%) to be the greatest opportunity areas in drug development in clinical trials
积分充值
30积分
6.00元
90积分
18.00元
150+8积分
30.00元
340+20积分
68.00元
640+50积分
128.00元
990+70积分
198.00元
1640+140积分
328.00元
微信支付
余额支付
积分充值
应付金额:
0 元
请登录,再发表你的看法
登录/注册